Pharmacotherapy of Adult Attention Deficit/Hyperactivity Disorder (Q40434225)

20 September 2017

1 reference

title

Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review (English)

1 reference

20 September 2017

Pharmacotherapy of Adult Attention Deficit/Hyperactivity Disorder (English)

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

1 June 2024

0 references

1 reference

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

adult attention deficit hyperactivity disorder

1 reference

2

Biederman J

1 reference

20 September 2017

T. E. Wilens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7593710

1 June 2024

T. J. Spencer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7593710

1 June 2024

J. Prince

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7593710

1 June 2024

language of work or name

English

0 references

publication date

1 August 1995

1 reference

full work available at URL

20 September 2017

http://journals.lww.com/00004714-199508000-00006

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Journal of Clinical Psychopharmacology

1 June 2024

published in

1 reference

20 September 2017

volume

15

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

270-279

1 reference

DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population

20 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. The use of combined measures

1 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

A survey of medication treatment for hyperactive/inattentive students

1 June 2024

3

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Psychiatric illness in the families of hyperactive children.

1 June 2024

4

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Hyperkinetic behavior syndrome in children

1 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Hyperkinetic adult. Study of the "paradoxical" amphetamine response

1 June 2024

8

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report

1 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Hyperactive boys almost grown up. I. Psychiatric status

1 June 2024

10

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

1 June 2024

11

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Hyperactive boys almost grown up. V. Replication of psychiatric status.

1 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Is attention-deficit hyperactivity disorder in adults a valid disorder?

1 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Gender differences in a sample of adults with attention deficit hyperactivity disorder.

1 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders

1 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

1 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state

1 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Cerebral glucose metabolism in adults with hyperactivity of childhood onset

1 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder

1 June 2024

19

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height

1 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy.

1 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

A review of stimulant drug research with hyperactive children

1 June 2024

22

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Methylphenidate effects on symptoms of attention deficit disorder in adults.

1 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Attention deficit disorder ('minimal brain dysfunction') in adults. A replication study of diagnosis and drug treatment

1 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults

1 June 2024

26

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

1 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Attention deficit disorder ('minimal brain dysfunction') in adults. A replication study of diagnosis and drug treatment

1 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance.

1 June 2024

31

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Methylphenidate in Hyperkinetic Children: Differences in Dose Effects on Learning and Social Behavior

1 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Clinical correlates of methylphenidate blood levels.

1 June 2024

33

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey

1 June 2024

34

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour

1 June 2024

35

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Tricyclic antidepressants in the treatment of children with attention deficit disorder

1 June 2024

36

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Adult attention deficit hyperactivity disorder and desipramine

1 June 2024

37

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder

1 June 2024

38

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Bupropion treatment of attention-deficit hyperactivity disorder in adults

1 June 2024

40

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy

1 June 2024

41

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

An open trial of pargyline in the treatment of attention deficit disorder, residual type

1 June 2024

42

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Nomifensine maleate in adult attention deficit disorder

1 June 2024

44

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial

1 June 2024

46

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Beta blockers for aggression: a review of the pediatrie experience

1 June 2024

48

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Journal of the American Academy of Child and Adolescent Psychiatry

1 June 2024

51

30

762

Barrickman

1991

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome

1 June 2024

52

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type

1 June 2024

53

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Effects of levodopa on attention deficit disorder, residual type

1 June 2024

54

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Treatment of attention deficit disorder with DL-phenylalanine

1 June 2024

55

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology

1 June 2024

56

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function.

1 June 2024

57

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder

1 June 2024

58

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?

1 June 2024

59

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison

1 June 2024

60

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Stimulant drug treatment of hyperactivity: biochemical correlates.

1 June 2024

62

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity

1 June 2024

63

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment

1 June 2024

64

1 reference

https://api.crossref.org/works/10.1097/00004714-199508000-00006

1 June 2024

Identifiers

1 reference

20 September 2017

1 reference